• Genentech’s investigational divarasib outperformed sotorasib or adagrasib in the Phase III Krascendo 1 trial in previously treated KRAS G12C-mutated non-small cell lung cancer.
• Patients receiving divarasib lived longer and experienced delayed disease progression compared with those receiving the current treatments.
• No new safety signals emerged; fewer patients stopped treatment because of treatment-related adverse events.
• Results were presented at the 2026 ESMO Congress and simultaneously published in The New England Journal of Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.